Baxter Biotech Group
Executive Summary
Adds fourth business operation with establishment of Gene Therapy unit to consolidate research efforts being undertaken at Round Lake, Illinois, Santa Ana, California and the Weizmann Institute of Science in Israel, Baxter announces Aug. 24. Bill Johnson, PhD, is general manager of the unit and a VP of Baxter Healthcare. The Baxter Biotech Group, formed in 1992 from the company's blood products businesses, includes Hyland, Fenwal Automated Systems and the Immunotherapy Group. Gene therapy researchers at Baxter are working on, among other projects, a Factor VIII therapy; an implantable system for hemophiliacs to deliver genetically altered material; and a cancer therapy that "splices the cancer-adhering capability of a monoclonal antibody into T-cell receptors," the company reports.
You may also be interested in...
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Shire Hopes To Sow Future Deals With $50M Venture Fund
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth